1. Lim H, Kang HG, Kim KH. Antivenom for snake bite in Korea. J Korean Med Assoc. 2013; 56:1091–103.
Article
2. Ruha AM, Kleinschmidt KC, Greene S, et al. The epidemiology, clinical course, and management of snakebites in the North American Snakebite Registry. J Med Toxicol. 2017; 13:309–20.
Article
3. Walter FG, Stolz U, Shirazi F, McNally J. Epidemiology of severe and fatal rattlesnake bites published in the American Association of Poison Control Centers' Annual Reports. Clin Toxicol (Phila). 2009; 47:663–9.
Article
5. Choi HJ, Lee DW, Ryu HR, Kim JH, Lee JH. Case of treatment of snakebite on finger with topical oxygen therapy. Arch Hand Microsurg. 2020; 25:292–6.
Article
6. Corbett B, Clark RF. North American snake envenomation. Emerg Med Clin North Am. 2017; 35:339–54.
Article
7. Mascarenas DN, Fullerton L, Smolinske SC, Warrick BJ, Seifert SA. Comparison of F(ab’)2 and Fab antivenoms in rattlesnake envenomation: first year’s post-marketing experience with F(ab’)2 in New Mexico. Toxicon. 2020; 186:42–5.
Article
8. Gao JF, Wang J, Qu YF, Ma XM, Ji X. Immunoreactivity between venoms and commercial antiserums in four Chinese snakes and venom identification by species-specific antibody. J Immunol Methods. 2013; 387:211–8.
Article
9. Lavonas EJ, Ruha AM, Banner W, et al. Unified treatment algorithm for the management of crotaline snakebite in the United States: results of an evidence-informed consensus workshop. BMC Emerg Med. 2011; 11:2.
Article